Xyloketal B (Xyl-B) is a novel marine compound isolated from mangrove fungus Xylaria sp. (No 2508). We previously showed that Xyl-B promoted endothelial NO release and protected against atherosclerosis through the Akt/eNOS pathway. Vascular NO production regulates vasoconstriction in central and peripheral arteries and plays an important role in blood pressure control. In this study, we examined whether Xyl-B exerted an antihypertensive effect in a hypertensive rat model, and further explored the possible mechanisms underlying its antihypertensive action. Administration of Xyl-B (20 mg·kg -1 ·d -1
Introduction
Hypertension is a major risk factor that predisposes patients to cardiovascular disorders and has high rates of morbidity and mortality. Emerging data implicate increases in systemic oxidative stress [1] and vascular inflammation [2] in the pathogene-www.nature.com/aps Zhao LY et al Acta Pharmacologica Sinica sis of hypertension. Endothelial dysfunction, which manifests as impaired nitric oxide (NO) bioactivity, is an important early event associated with impaired vessel diastolic function [3] and mainly results from increased nitric oxide (NO) degradation due to interactions between NO and superoxide anions. Pharmacological approaches to restore endothelial function or complement NO have been demonstrated to have antihypertensive effects. Marine organisms are abundant natural sources of novel bioactive compounds because they can produce a variety of molecules with unique structural features and exhibit various types of biological activities. Xyloketal B (Xyl-B), obtained from the South China Sea Coast, is one of a series of novel ketal compounds isolated from the mangrove fungus Xylaria sp (No 2508) [4, 5] . In previous studies, multiple biomedical activities of Xyl-B have been demonstrated, including neuroprotective effects against toxicity [6] , antioxidant effects on endothelial cells [7] and zebrafish [8] , anti-glioma effects [9] and reduced atherosclerosis plaque formation in apolipoprotein E-deficient mice [10] . After exploring the underlying mechanisms, we have found that Xyl-B can directly scavenge DPPH free radicals, promote endothelial NO release [7] and increase eNOS phosphorylation at Ser-1177 in a concentration-and time-dependent manner [10] . Furthermore, the effect of Xyl-B on aortic tension was also evaluated, and the data indicated that Xyl-B can improve NO-dependent aortic vasorelaxation in atherosclerotic ApoE −/− mice [10] and exert potent vasorelaxant activity on KCl-induced contractions in isolated rat aortic rings [11] . Based on these findings, we hypothesize that Xyl-B may regulate vascular tone through the endothelial NO system and thus has an effect on blood pressure control.
Therefore, in the present study, we established a 2-kidney, 2-clip (2K2C) renovascular hypertensive rat model to evaluate the effects of Xyl-B in the development of hypertension. In addition, we further explored the possible mechanisms for the antihypertensive effects of Xyl-B, including Xyl-B-mediated vasorelaxation, endothelial nitric oxide synthase (eNOS) bioactivity, the NO-sGC-cGMP pathway and the prostacyclin pathway. Abnormal calcium signaling has been demonstrated to regulate arterial tone in the development of hypertension in both human patients and animal models. Consequently, Ca 2+ channel blockers are commonly used as anti-hypertensive agents. Because we found that Xyl-B suppressed KCl-and phenylephrine (Phe)-induced contractions in endotheliumdenuded thoracic aortic rings, which could not be completely explained by the endothelium-dependent pathway, the influence of Xyl-B on calcium signaling in vascular smooth muscle cells was also investigated.
Materials and methods

Chemicals and reagents
Xyl-B was isolated by the Department of Applied Chemistry, Sun Yat-sen University (Guangzhou, China). The identity and purity of the compound were characterized by HPLC and 2 D-NMR as previously described [4] . Xyl-B was dissolved in dimethyl sulfoxide (DMSO) and stored at -20°C until use.
The final concentration of DMSO in culture media was less than 0.1%. Phenylephrine (Phe), acetylcholine (ACh), sodium nitroprusside (SNP) and N G -nitro-L-arginine methyl ester (L-NAME) were purchased from Sigma (St Louis, MO, USA). Methylene Blue was obtained from Merck (Massachusetts, USA). [ 3 H]L-arginine was obtained from Beijing Institute of Nuclear Industry (Beijing, China). All other reagents used were purchased from Sigma unless otherwise specified.
Animals and experimental design
All experimental animal procedures and protocols were approved by the Sun Yat-sen University Committee for Animal Research and were conducted in accordance with the National Research Council's guidelines. 2K2C stroke-prone renovascular hypertension was induced in male SpragueDawley rats (60-80 g, purchased from the Experimental Animal Center of Sun Yat-sen University) as described previously [12, 13] . All rats were randomly divided into 5 groups: (1) the Sham group: sham-operated control group; (2) the Htn group: 2K2C-operated hypertensive group; (3) the propylene glycol-treated hypertensive (Htn+Sol) group: the rats received an intraperitoneal injection of 2 mL of saline solution containing 20% propylene glycol once daily after surgery; (4) the Htn +Xyl-B group: 2K2C rats received an intraperitoneal injection of Xyl-B (20 mg·kg -1 ·d -1 in 2 mL of saline solution containing 20% propylene glycol) after surgery; and (5) the Htn+Cap group: 2K2C rats were treated with captopril (0.1 mg·kg -1 ·d -1 , ig). The sham-operated animals underwent sham procedures without clip placement. Body weight and SBP or DBP measured by tail cuff plethysmography [13] were recorded every two weeks until 12 weeks after operation.
Vascular reactivity experiments in aortic rings
Aortic rings were prepared and vascular reactivity experiments were performed as previously described [14] . Briefly, Sprague-Dawley rats (200-250 g) were euthanized and their aortas were quickly removed and placed into ice-cold Kreb's solution (composition in mmol/L: NaCl 119, KCl 4.7, KH 2 PO 4 1.18, MgSO 4 1.17, NaHCO 3 25, CaCl 2 2.5, EDTA 0.026, and glucose 5.5) where they were freed of fatty and connective tissues. Aortic ring segments (3-5 mm) were then cut and each segment was mounted onto separate Mulvany myograph chambers, which involved placing each ring onto two stainless hooks in an isometric myograph filled with Kreb's solution (5 mL) aerated with 95% O 2 /5% CO 2 and maintained at 37 °C. Changes in isometric force were recorded online using a Multi-myograph data acquisition system with PowerLab software (AD Instruments, Inc). The rings were stretched to an optimal resting tension (1.5 g) and allowed to stabilize for 2 h. An additional equilibration period of 30 min was allotted before treatment with any drugs. The rings were stimulated with Phe (1 μmol/L) when indicated to induce contraction. To examine the possible mechanisms of the vaso-relaxant effects of Xyl-B, the NO synthase (NOS) inhibitor L-NAME (100 μmol/L), the soluble guanylate cyclase inhibitor methylene blue (MB, 10 μmol/L) or the cyclooxygenase inhibitor eNOS activity detection in human umbilical vascular endothelial cells (HUVECs) Primary culture of HUVECs was performed using collagenase digestion of the human umbilical cord as described previously [7] . Three to six generations of identified HUVECs were used in this experiment. Cells were pre-incubated with 20 µmol/L of Xyl-B for 0, 15 [15] .
Measurement of cyclic GMP in primary cultured VSMCs
Vascular smooth muscle cells (VSMCs) were isolated from adult rat thoracic aortas by the explants method as previously described [16] . Passages 3 to 6 showing >99% positive immunostaining against α-smooth muscle-actin (α-SMA) were used for the experiments, and cells at 80% confluence were arrested by serum-starvation for 24 h. Cyclic GMP (cGMP) levels in VSMCs were determined using Parameter TM Cyclic GMP Assay kits (R&D Systems, Minnesota, USA) according to the manufacturer's instructions. The cells were divided into a VSMC mono-culture group and a VSMC-HUVEC co-culture group. Each group of cells was treated with DMSO, SNP (10 µmol/L), or Xyl-B (20 and 40 µmol/L) and the incubation time was 30 min. None of the drugs exhibited cytotoxicity at any dose used (evaluated by MTT assay, data not shown).
Determination of single-cell intracellular Ca
2+ was detected by Fluo-3/AM staining as described previously [17] . Cells plated in 35-mm petri dishes were loaded with Fluo-3/AM (10 µmol/L, Sigma) in Kreb's solution at 37 ºC for 30 min and then exposed to KCl (60 mmol/L). Xyl-B was added 5 min prior to KCl stimulation. The dishes were washed twice with Kreb's solution to remove unhydrolyzed indicator before transfer to a chamber where the drugs were added. Cellular real-time fluorescence (E x488 nm , E m522 nm ) was measured using a confocal microscope (FV500-IX 81, OLYMPUS, Japan). A change in fluorescence was expressed as F/F 0 , where F represents the fluorescence intensity (F) of each pixel in the original fluorescence image and F 0 is defined as the F value at the beginning of the images when the cell was assumed to be in a resting state.
Statistical analysis
All values are expressed as the means±SEM. The data were analyzed by a two-tailed unpaired Student's t-test between 2 groups and by one-way ANOVA followed by the Bonferroni post hoc test for 3 or more groups. The analyses were performed using GraphPad Prism Software (GraphPad Software Inc, La Jolla, CA, USA). A P value <0.05 was considered statistically significant.
Results
Xyl-B decreases blood pressure in 2K2C hypertensive rats First, we assessed the antihypertensive effects of Xyl-B using the 2K2C hypertensive rat model and blood pressures were measured 0, 2, 4, 6, 8, 10 and 12 weeks after the operation. As shown in Figure 1A and 1B, systolic blood pressure (SBP) and diastolic blood pressure (DBP) in the hypertension (Htn) group increased progressively at 2, 4, 6, 8, 10 and 12 weeks after the operation, which is consistent with our previous report [18, 19] . Xyl-B at 20 mg·kg -1 ·d -1 was administered to the 2K2C rats intraperitoneally; saline solution containing 20% Xyl-B reduces aortic tension in response to phenylephrine Xyloketals have been demonstrated to exert vaso-relaxant activities in KCl-induced vasoconstriction that were stronger in endothelium-intact rings than in denuded rings, suggesting that the vaso-relaxant effect of these compounds may be mediated by endothelium-dependent mechanisms [11] . Hypertension is closely related to vascular tone, and our previous studies have suggested that Xyl-B plays an important role in endothelial NO synthesis, which mediates vessel relaxation. To further confirm whether Xyl-B protects against hypertension by affecting vascular tension, thoracic aorta constriction in response to Phe was measured. As shown in Figure 2 , Xyl-B significantly inhibited Phe-induced vasoconstriction at concentrations of 10 -6 mol/L and 10 -5 mol/L. Interestingly, the inhibition effect was partly reversed by L-NAME, the inhibitor of endothelial nitric oxide synthetases (eNOS); however, a significant difference was observed in vessel tension between the Xyl-B+L-NAME group and the solvent control group at 10 -5 mol/L.
Xyl-B inhibits aortic vasoconstriction through the NO-sGC-cGMP pathway To identify the pathway through which Xyl-B exerts its antihypertensive effect, we first detected Xyl-B's influence on acetylcholine (ACh)-and sodium nitroprusside (SNP, an exogenous NO provider)-induced vessel diastole in Phe precontracted vessels. As shown in Figure 3 , Xyl-B enhanced the vaso-relaxant effect of ACh, but not SNP, indicating that Xyl-B decreases vessel tension through the endothelium-dependent NO-related pathway, which is consistent with Figure 2 .
Endothelium-dependent vasodilation is regulated primarily by NO but also by prostacyclin (PGI 2 ) and an unidentified endothelium-derived hyperpolarizing factor. NO and PGI 2 are the predominant endogenous endothelial vaso-relaxant substances [20] . The NO-sGC-cGMP signaling cascade plays an essential role in vascular smooth muscle relaxation, and clinical studies indicate that endothelium-derived NO is involved in normal and pathological blood pressure regulation. PGI 2 is produced by the cyclooxygenases, COX-1 and COX-2, which form the prostaglandin endoperoxide PGG 2 . This is converted to PGH 2 , which is then transformed enzymatically into PGI 2 by prostacyclin synthase. To determine whether the PGI 2 pathway is also altered by Xyl-B, indomethacin (IMC, 10 μmol/L) was used to inhibit PGI 2 production by depressing COX-1, while methylene blue (MB, 10 μmol/L) was applied to inhibit sGC to interrupt the NO-sGC-cGMP pathway. As shown in Figure 3B , IMC did not alter the inhibitory effect of Xyl-B on vasocontractions provoked by Phe (1 μmol/L), which was significantly reversed by MB, indicating that the NO-sGC-cGMP pathway mediates the anti-hypertensive effect of Xyl-B rather than PGI 2 .
In addition, we detected eNOS activity in HUVECs, which was measured as the conversion% of [
3 H]L-citrulline transformed from [ 3 H]L-arginine. As shown in Figure 4A , Xyl-B increased endothelial eNOS bioactivity in a dose-and timedependent manner. Moreover, Xyl-B increased the cGMP level of co-cultured VSMC-HUVECs, but not mono-cultured VSMCs ( Figure 4B ).
Xyl-B attenuates smooth muscle cell (SMC) Ca
2+ signaling As shown above, Xyl-B inhibited vascular constriction in response to KCl and Phe and this effect could not be completely eliminated by pre-incubation with L-NAME, suggesting that Xyl-B worked through other pathways or factors in addition to NO. As PGI 2 production in the endothelium was excluded (Figure 5) [21] . Therefore, to investigate whether Xyl-B has an effect on the [Ca 2+ ] i in SMCs, we first detected the effect of Xyl-B on KCl-induced Ca 2+ entry in SMCs and found that Xyl-B significantly suppressed the Ca 2+ entry stimulated by KCl (60 mmol/L), as shown in Figure 5A . Then, we determined the influence of Xyl-B on Ca 2+ release from the ER using ryanodine (10 -7 mol/L). As shown in Figure 5B , Xyl-B pre-incubation obviously decreased ryanodineinduced vasoconstriction.
Discussion
This study demonstrates the antihypertensive effects of Xyl-B and the main findings are as follows: (1) 20 mg·kg -1 ·d -1 of Xyl-B significantly reduced SBP and DBP in the 2K2C hypertensive rat model, providing evidence for Xyl-B's in vivo antihypertensive effect for the first time. (2) Xyl-B decreased vascular tension in response to KCl and phenylephrine in thoracic aortas, which was partly reversed by incubation with L-NAME. (3) Xyl-B inhibited aortic vasocontractions through the endothelial NO-sGC-cGMP pathway rather than the PGI 2 pathway. (4) Xyl-B regulated smooth muscle Ca 2+ signaling by affecting both voltage-dependent Ca 2+ entry (VDCC) and store-operated Ca 2+ entry (SOCE) in vascular smooth muscle cells ( Figure 6 ). The 2K2C model is a widely used renovascular hypertension model [12] with significant value for assessing whether a drug has potential antihypertensive effects. Therefore, in this study, 2K2C hypertensive rats were used to evaluate Xyl-B's antihypertensive effects, and the results showed that Xyl-B could significantly decrease SBP and DBP in this model. Our previous studies demonstrated that Xyl-B can directly scavenge free radicals, promote endothelial NO release [7] and protect the functions of mitochondria and the endothelium [6] . We suppose that these endothelium-dependent mechanisms may contribute to the antihypertensive effects of Xyl-B. The endothelium regulates vascular homeostasis by modulating vasomotor tone through the production of several vasoactive mediators, including NO and prostacyclin [22, 23] . In the development of hypertension, endothelial dysfunction precedes increases in blood pressure and predisposes patients to structural vascular changes [24, 25] . Endothelial dysfunction is characterized by reduced NO levels or bioavailability [26] . Classically, NO is generated from L-arginine by the binding of Ca
2+
-calmodulin to eNOS [27] . NO released from endothelial cells stimulates soluble guanylate cyclase (sGC), leading to a sequential increase in the cGMP level in VSMCs [28] , which in turn activates cGMP-dependent protein kinase and leads to increased extrusion of Ca 2+ from the cytosol in VSMCs and inhibition of the contractile machinery [28, 29] . In the present study, both the eNOS inhibitor L-NAME and the sGC inhibitor MB suppressed the endothelium-dependent vasorelaxation induced by Xyl-B, but the cyclooxygenase blocker (indomethacin) could not. In addition, the cGMP-enhancing effect of Xyl-B was observed in VSMCs co-cultured with HUVECs, but not in the VSMC mono-culture. These data demonstrated that the endothelium-dependent vaso-relaxant activities of Xyl-B are attributed to the NO-sGC-cGMP signaling pathway rather than PGI 2 .
eNOS activity is known to be regulated by various intracellular signals, resulting in phosphorylation of eNOS [30] , and eNOS phosphorylation by the upstream PI3K/Akt pathway is required for efficient NO production [31, 32] . Xyl-B has been shown to promote NO release and eNOS bioactivity in HUVECs [8] , which was confirmed in the present study through detection of the conversion ratio of
3 H]L-citrulline. Our recent study showed that Xyl-B could increase eNOS activity by regulating phosphorylation of Akt and eNOS at Ser 1177 and Thr 495 [10] . Although many aspects of Xyl-B as a novel drug candidate for protecting the vascular endothelium have been identified and found to be effective for the treatment of cardiovascular diseases such as atherosclerosis [7, 8, 10, 11] , further experiments are required to confirm the role of the eNOS-dependent mechanism in the antihypertensive action of Xyl-B.
Our previous reports showed marked differences between endothelium-intact (EC 50 =19 μmol/L) and endotheliumdenuded (EC 50 =41 μmol/L) aortic rings after Xyl-B treatment [10, 11] , suggesting that Xyl-B may exert vaso-relaxant activities by endothelium-dependent mechanisms and by endothelium-independent mechanisms to a lesser extent. Interestingly, when we investigated the endothelial NO pathway using L-NAME, L-NAME could only partly reverse Xyl-B's vaso-relaxant effect on Phe-stimulated pre-contracted aortic rings, but it could not eliminate this effect as a significant difference remained between the solvent control group and the Xyl-B+L-NAME group, indicating that other mechanisms independent of the NO system may be involved.
In addition to endothelial NO, vascular smooth muscle dysfunction is another important cause of hypertension [33] . Abnormal regulation of intracellular Ca 2+ in VSMCs contributes to the pathogenesis of hypertension and also contributes to vascular and cardiac remodeling secondary to hypertension. Two types of Ca 2+ channels exist in VSMCs: VDCCs and voltage-independent Ca 2+ channels (including receptoroperated Ca 2+ channels and store-operated channels) [34] . Ca 2+ channel blockers (CCBs) are clinically useful vasodilators and are widely used in the treatment of hypertension and related cardiovascular diseases [35] . CCBs lower blood pressure through a well-characterized mechanism of blocking L-type voltage-dependent Ca 2+ channels in vascular cells to restore Ca 2+ homeostasis [36] . Our previous data indicated that some xyloketals, including Xyl-B, can attenuate L-type Ca 2+ currents in primary cultured hippocampal cells from newborn rats using patch-clamp experiments [21] , and the current study indicates that Xyl-B dilated Phe-or KCl-induced precontracted thoracic aortic rings. Phe-induced contractions in aortic rings are mainly mediated by Ca 2+ entry via voltage-independent Ca 2+ channels, such as SOCE, while KCl mainly activated the L-type Ca 2+ channels (VDCCs). In the present study, we detected the effect of Xyl-B on KCl-induced Ca 2+ entry in SMCs and on ryanodine-induced aortic contraction. The results not only further confirmed the L-type Ca 2+ channel-blocking effect of Xyl-B in smooth muscle cells but also indicated that Xyl-B may affect SOCE, warranting further investigation of the exact [21] , but they had no effects on KCl-induced contractions of rat thoracic aortic rings and their effects could be completely inhibited by nifedipine (data not shown). Among the screened xyloketal compounds, only Xyl-B showed significant antihypertensive effects with minor inhibitory effects on VDCCs in newborn rat hippocampal cells (12.05%). These data suggest that the influence of Xyl-B on Ca 2+ signaling in different tissues and cell types should be interpreted with caution. Based on the current results, whether regulation of Ca 2+ signaling by Xyl-B is the predominant mechanism of its effects in hypertension remains unknown.
Furthermore, during the development of renovascular hypertension, major structural alterations in the heart include left ventricular (LV) hypertrophy and fibrosis [13] . The cardiovascular remodeling associated with hypertension involves oxidative stress and enhanced matrix metalloproteinase (MMP) expression/activity [13] . CCBs shows beneficial effects on left ventricular (LV) hypertrophy and fibrosis via antioxidative mechanisms [37] . The data observed in our current study show that Xyl-B can reverse cardiac remodeling and fibrosis in 2K2C rats (unpublished data). Therefore, Xyl-B not only attenuates the high BP level in hypertension but may also ameliorate the complications of hypertension.
In summary, this is the first study to demonstrate that Xyl-B can reduce blood pressure in 2K2C renovascular hypertensive rats. Our results suggest that Xyl-B induces relaxation in rat aortic rings through an endothelium-dependent pathway mediated by the NO-sGC-/cGMP pathway and through an endothelium-independent pathway involving VDCC blockade mediated by Ca 2+ entry in VSMCs. One study limitation is that neither the NO-sGC-/cGMP pathway nor the Ca 2+ signaling mechanisms underlying Xyl-B's antihypertensive effects were verified in VSMCs. Therefore, the mechanisms of the antihypertensive action of Xyl-B should be interpreted with caution, and further in vivo studies are warranted to determine the precise mechanism. Taken together, the findings of this study support Xyl-B as a potential new drug candidate for the treatment of hypertension. Vascular tone is the result of joint regulation of endothelium and smooth muscle and endothelium-dependent vasodilation is regulated primarily by NO-sGC-cGMP signaling cascade and prostacyclin (PGI 2 ) in vascular smooth muscle cells. PGI 2 is produced by the cyclooxygenases, COX-1 and COX-2, which form the prostaglandin endoperoxide PGG 2 , PGG 2 is converted to PGH 2 which is then transformed enzymatically into PGI 2 by prostacyclin synthase. Our present study demonstrated that Xyl-B affected eNOS activity and cGMP level, and sGC was also involved but PGI 2 pathway was not. Additionally, as Xyl-B's inhibitory effect on vasoconstriction could not be completely explained by endothelial pathway, we furtherly found that Xyl-B regulated vascular tone by affecting both voltage dependent calcium entry (VDCC) and store-operated calcium entry (SOCE) in vascular smooth muscle cells.
